Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961924 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL5913543 | 0.85 | LMNA (0.56) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL3720206 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL14798532 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL97957 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL5913325 | 0.84 | PDK1 (0.51) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL16233087 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL31090163 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL3720077 | 0.83 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1HTTLMNAGAA | |
| SCHEMBL5913083 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1HTTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | SMN1; SMN2 4110/4885ALDH1A1 2632/4885HTT 1770/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | SMN1; SMN2 4036/4885ALDH1A1 2449/4885HTT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.